Information Provided By: 
Fly News Breaks for February 22, 2017
ANIP
Feb 22, 2017 | 08:28 EDT
Roth Capital analyst Scott Henry downgraded ANI Pharmaceuticals to Neutral from Buy, with a $69 price target, as he awaits 2017 financial guidance. The analyst has near-term concerns with the recent market share decline for the EEMT franchise. However, he notes that the long-term prospects remain more focused on the emergence of corticotropin as a material revenue generator.
News For ANIP From the Last 2 Days
There are no results for your query ANIP
